Aptahem AB (publ) (NGM:APTA)
0.5660
-0.0700 (-11.01%)
At close: Jun 11, 2026
Aptahem AB Revenue
Aptahem AB had revenue of 575.00K SEK in the quarter ending March 31, 2026, a decrease of -6.81%. This brings the company's revenue in the last twelve months to 2.52M, down -26.52% year-over-year. In the year 2025, Aptahem AB had annual revenue of 2.59M, down -32.73%.
Revenue (ttm)
2.52M
Revenue Growth
-26.52%
P/S Ratio
5.83
Revenue / Employee
839.36K
Employees
3
Market Cap
14.68M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.59M | -1.26M | -32.73% |
| Dec 31, 2024 | 3.84M | -6.62M | -63.28% |
| Dec 31, 2023 | 10.46M | 7.02M | 203.47% |
| Dec 31, 2022 | 3.45M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Magle Chemoswed Holding AB | 273.25M |
| Alzinova AB | 25.66M |
| Fluicell AB | 20.15M |
| ExpreS2ion Biotech Holding AB | 16.12M |
| Spago Nanomedical AB | 4.38M |
| Biosergen AB | 2.09M |
| 2cureX AB | 1.98M |
| Pila Pharma AB | 1.13M |
Aptahem AB News
- 14 days ago - Aptahem AB Quarterly report: Q1 2026 - Filings
- 4 months ago - Aptahem AB Annual report: Q4 2025 - Filings
- 4 months ago - Aptahem AB Quarterly report: Q4 2025 - Filings
- 6 months ago - Aptahem AB Quarterly report: Q3 2025 - Filings
- 8 months ago - Aptahem AB Transcript: Status Update - Transcripts
- 8 months ago - Aptahem AB Press release: Status Update - Filings
- 9 months ago - Aptahem AB Press release: Status Update - Filings
- 10 months ago - Aptahem AB Quarterly report: Q2 2025 - Filings